Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.0K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

455
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
455
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

848
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
848
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

781
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
781
Common Respiratory Disorders01:31

Common Respiratory Disorders

1.3K
Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
1.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

786
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
786

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Funding for School Based Health Care Mental Health Services is Essential for Latino Youth.

Journal of health care for the poor and underserved·2026
Same author

Rotavirus Vaccines Are Safe and Effective: So Why Aren't All Children Protected?

Pediatrics·2026
Same author

Influence of Community-Level Factors on Health Care Provider Recommendations for HPV Vaccine.

Pediatrics open science·2026
Same author

Childhood Vaccine Hesitancy.

The New England journal of medicine·2026
Same author

Penicillin allergy removal on history alone: delabeling outcomes in a pediatric cohort.

The journal of allergy and clinical immunology. In practice·2026
Same author

Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years.

Pediatrics·2026

Related Experiment Video

Updated: Jan 15, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K

Clinical progress note: Respiratory syncytial virus.

Justin B Searns1,2, Sean T O'Leary2

  • 1Department of Pediatrics, Section of Hospital Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.

Journal of Hospital Medicine
|October 13, 2025
PubMed
Summary
This summary is machine-generated.

New respiratory syncytial virus (RSV) immunizations offer hope, potentially preventing millions of hospitalizations and deaths worldwide. This review examines the evidence and impact of these vital new vaccines.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K

Related Experiment Videos

Last Updated: Jan 15, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.5K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.0K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.3K

Area of Science:

  • Immunology
  • Public Health
  • Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) causes significant global morbidity and mortality, with over 3.6 million hospitalizations and 100,000 deaths annually.
  • Existing prevention strategies for RSV are limited, highlighting the urgent need for effective interventions.

Purpose of the Study:

  • To review the evidence supporting recently approved immunizations for respiratory syncytial virus (RSV).
  • To examine the potential public health impact of these new RSV immunization strategies in reducing hospitalizations and mortality.
  • To assess the role of these vaccines in mitigating the global burden of RSV.

Main Methods:

  • Literature review of clinical trial data and epidemiological studies on new RSV immunizations.
  • Analysis of healthcare cost-effectiveness and mortality reduction associated with RSV vaccination.
  • Examination of target patient populations for each approved immunization.

Main Results:

  • Three distinct RSV immunizations have been approved since 2023, each tailored to specific patient groups.
  • These immunizations demonstrate significant potential to prevent RSV-related hospitalizations.
  • The implementation of these vaccines is expected to reduce healthcare system costs and save lives.

Conclusions:

  • Newly approved RSV immunizations represent a major advancement in preventing severe respiratory illness.
  • These vaccines are poised to significantly decrease the global burden of respiratory syncytial virus.
  • Further research and implementation strategies are crucial to maximize the public health benefits of RSV vaccination.